Published in Thromb Res on July 26, 2012
Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost (2016) 0.86
The discovery of dabigatran etexilate. Front Pharmacol (2013) 0.86
Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy. Ann Pharmacother (2016) 0.75
The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review. Clin Res Cardiol (2017) 0.75
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med (2015) 18.66
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med (2008) 6.00
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet (2007) 5.41
Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost (2010) 4.45
A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation (2006) 2.54
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost (2011) 2.53
Nongenomic steroid action: controversies, questions, and answers. Physiol Rev (2003) 2.41
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty (2008) 2.30
Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery. Thromb Haemost (2012) 1.94
Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thromb Haemost (2013) 1.83
Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost (2008) 1.64
Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis (2012) 1.63
Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol (2005) 1.58
Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost (2009) 1.58
Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies. Europace (2013) 1.53
Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost (2012) 1.51
Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res (2008) 1.47
Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation. Anesthesiology (2014) 1.42
Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery. Clin Pharmacokinet (2008) 1.39
Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol (2010) 1.31
Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. Thromb Haemost (2014) 1.22
Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference. Europace (2013) 1.16
Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty. Clin Appl Thromb Hemost (2009) 1.14
Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care (2013) 1.14
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™). Cardiovasc Diabetol (2014) 1.12
Health technology assessment and its role in the future development of the Indian healthcare sector. Perspect Clin Res (2012) 1.11
Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation. J Clin Pharmacol (2011) 1.11
Clinical and biochemical prediction of early fatal outcome following hip fracture in the elderly. Int Orthop (2010) 1.08
Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res (2007) 1.08
Stroke prevention in atrial fibrillation--an Asian stroke perspective. Heart Rhythm (2013) 1.07
Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate. Thromb Haemost (2010) 1.06
Interpretation of point-of-care INR results in patients treated with dabigatran. Am J Med (2012) 1.04
Population-based cohort study of warfarin-treated patients with atrial fibrillation: incidence of cardiovascular and bleeding outcomes. BMJ Open (2014) 1.04
Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool. Haematologica (2003) 1.00
Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected]. Int Orthop (2011) 0.98
Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. Thromb Res (2012) 0.98
Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet (2002) 0.97
Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials. Circ Cardiovasc Qual Outcomes (2010) 0.96
Perioperative mortality in hip fracture patients treated with cemented and uncemented hemiprosthesis: a register study of 11,210 patients. Int Orthop (2013) 0.95
Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database. Thromb Haemost (2013) 0.95
An electronic tool for venous thromboembolism prevention in medical and surgical patients. Haematologica (2006) 0.94
Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study. J Am Coll Cardiol (2012) 0.93
Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness. Thromb Haemost (2012) 0.90
Blood loss in cemented THA is not reduced with postoperative versus preoperative start of thromboprophylaxis. Clin Orthop Relat Res (2012) 0.88
Evaluation of the acute coronary syndrome safety profile of dabigatran etexilate in patients undergoing major orthopedic surgery: findings from four Phase 3 trials. Thromb Res (2012) 0.88
Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile. Eur J Clin Pharmacol (2012) 0.88
Characteristics of patients with non-valvular atrial fibrillation using dabigatran or warfarin in the US. Curr Med Res Opin (2014) 0.88
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies. Thromb Haemost (2007) 0.87
Porcine spermatozoa contain more than one membrane progesterone receptor. Int J Biochem Cell Biol (2004) 0.86
Pharmacometric characterization of dabigatran hemodialysis. Clin Pharmacokinet (2013) 0.86
The discovery of dabigatran etexilate. Front Pharmacol (2013) 0.86
Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost (2003) 0.85
Preoperative versus postoperative initiation of dalteparin thromboprophylaxis in THA. Hip Int (2010) 0.85
Pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects after oral administration of dabigatran etexilate. Thromb Haemost (2011) 0.83
Acute effects of aldosterone on intracardiac monophasic action potentials. Int J Cardiol (2002) 0.83
Early aldosterone up-regulated genes: new pathways for renal disease? Kidney Int (2003) 0.83
Nongenomic effects of aldosterone: cellular aspects and clinical implications. Steroids (2002) 0.83
Nongenomic cardiovascular effects of triiodothyronine in euthyroid male volunteers. J Clin Endocrinol Metab (2002) 0.82
Effects of synthetic progestagens on autonomic tone, neurohormones and C-reactive protein levels in young healthy females in reproductive age. Int J Cardiol (2005) 0.82
Non-genomic aldosterone action: from the cell membrane to human physiology. J Steroid Biochem Mol Biol (2002) 0.82
Prevention of venous thromboembolism after hip or knee arthroplasty: findings from a 2008 survey of US orthopedic surgeons. J Arthroplasty (2011) 0.82
Publication rates of scientific presentations at the American Association of Hip and Knee Surgeons annual meetings from 1996 to 2001. J Arthroplasty (2006) 0.81
Quality of INR control and outcomes following venous thromboembolism. Clin Appl Thromb Hemost (2012) 0.80
Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost (2015) 0.80
Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thromb Haemost (2016) 0.80
Biochemical lung, liver and kidney markers and early death among elderly following hip fracture. Arch Orthop Trauma Surg (2012) 0.79
The proportion of perioperative mortalities attributed to cemented implantation in hip fracture patients treated by hemiarthroplasty. Hip Int (2014) 0.79
Efficacy of delayed thromboprophylaxis with dabigatran: pooled analysis. Thromb Res (2012) 0.79
D-Dimer and prothrombin fragment 1 + 2 in urine and plasma in patients with clinically suspected venous thromboembolism. Blood Coagul Fibrinolysis (2016) 0.79
Thrombin split products (prothrombin fragment 1 + 2) in urine in patients with suspected deep vein thrombosis admitted for radiological verification. Thromb Res (2013) 0.78
Treatment of venous thromboembolism - effects of different therapeutic strategies on bleeding and recurrence rates and considerations for future anticoagulant management. Thromb J (2012) 0.78
Insulin-Dependent Diabetes Mellitus: Islet Changes in Relation to Etiology and Pathogenesis. Endocr Pathol (1997) 0.78
Anticoagulant-related gastrointestinal bleeding--could this facilitate early detection of benign or malignant gastrointestinal lesions? Ann Med (2014) 0.77
Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty. Clin Orthop Relat Res (2008) 0.77
Lessons learned from the global orthopaedic registry: study design, current practice patterns, and future directions. Am J Orthop (Belle Mead NJ) (2010) 0.77
Novel approaches in the treatment of allergic rhinitis. Curr Opin Allergy Clin Immunol (2003) 0.77